In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA
Open accessAbstract
Our primary aim was to compare neuroinflammation in cognitively intact control subjects and patients with Alzheimer's disease (AD) by using positron emission tomography (PET) with translocator protein 18 kDa (TSPO)-specific radioligand [(18)F]-FEPPA. [(18)F]-FEPPA PET scans were acquired on a high-resolution research tomograph in 21 patients with AD (47- 81 years) and 21 control subjects (49-82 years). They were analyzed by using a 2-tissue compartment model with arterial plasma input function. Differences in neuroinflammation, indexed as [(18)F]-FEPPA binding were compared, adjusting for differences in binding affinity class as determined by a single polymorphism in the TSPO gene (rs6971). In grey matter areas, [(18)F]-FEPPA was significantly higher in AD compared with healthy control subjects. Large increases were seen in the hippocampus, prefrontal, temporal, parietal and occipital cortex (average Cohen's d= 0.89). Voxel-based analyses confirmed significant clusters of neuroinflammation in the frontal, temporal and parietal cortex in patients with AD. In white matter, [(18)F]-FEPPA binding was elevated in the posterior limb of the internal capsule, and the cingulum bundle. Higher neuroinflammation in the parietal cortex (r= -0.7, P= 0.005), and posterior limb of the internal capsule (r= -0.8, P=0.001) was associated with poorer visuospatial function. In addition, a higher [(18)F]-FEPPA binding in the posterior limb of the internal capsule was associated with a greater impairment in language ability (r= -0.7, P=0.004). Elevated neuroinflammation can be detected in AD patients throughout the brain grey and white matter by using [(18)F]-FEPPA PET. Our results also suggest that neuroinflammation is associated with some cognitive deficits.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with Alzheimer's disease, the presence of neuroinflammation detected by [18F]-FEPPA was positively correlated with the level of cognitive decline.
“In a study conducted by Suridjan I. et al., and including patients with Alzheimer’s disease, the presence of neuroinflammation detected by [18F]-FEPPA was positively correlated with the level of cognitive decline [72].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 72 · Cited by 132
Research works printed but not linked: 1
- [39]Wechsler D. Wechsler Adult Intelligence Scale– Third Edition (WAIS–III). Texas: Pearson Corp, San Antonio, 1997.
- Authors
- Suridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Corresponding author
- Mizrahi, R
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2015-02-24
- Volume
- 20
- Issue
- 12
- Pages
- 1579-1587
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8026116
- OpenAlex
- W2074905557
- Cited by
- 132
- References
- 72
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 15 · 2018: 14 · 2017: 19 · 2016: 9 · 2015: 6
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer Society
- National Institute of Mental Health (R01MH100043)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuroinflammation, [18F]FEPPA, translocator protein (TSPO), positron emission tomography, white matter, grey matter, internal capsule, cingulum, parietal cortex, visuospatial ability, language impairment, cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Anilides, Cognition Disorders, Encephalitis, Female, Fluorine Radioisotopes, Humans, Male, Middle Aged, Neuropsychological Tests, Pyridines, Radioligand Assay, Positron-Emission Tomography, White Matter, Gray Matter
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review